|
🐜
|
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
228 auth.
L. Paz-Ares,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
O. Voitko,
A. Poltoratskiy,
Santiago Ponce,
F. Verderame,
L. Havel,
...
I. Bondarenko,
A. Każarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
N. Shire,
Haiyi Jiang,
J. Goldman,
E. Batagelj,
Ignacio Casarini,
A. V. Pastor,
S. Sena,
J. Zarbá,
O. Burghuber,
S. Hartl,
B. Lamprecht,
M. Studnicka,
L. Schlittler,
Fabricio Augusto Martinelli de Oliveira,
A. Calabrich,
G. Girotto,
P. Reis,
Carlo Gorini,
Peo Rafael Martins De Marchi,
C. Baldotto,
C. Sette,
M. Zukin,
A. Dudov,
R. Ilieva,
K. Koynov,
R. Krasteva,
I. Tonev,
S. Valev,
V. Venkova,
M. Bi,
Chengshui Chen,
Yuan Chen,
Zhendong Chen,
J. Fang,
Jifeng Feng,
Zhigang Han,
Jie Hu,
Yi Hu,
Wei Li,
Zongan Liang,
Zhong Lin,
R. Ma,
Shenglin Ma,
K. Nan,
Y. Shu,
Kai Wang,
Mengzhao Wang,
Gang Wu,
N. Yang,
Zhi-Xiong Yang,
He-long Zhang,
Wei Zhang,
Jun Zhao,
Yanqiu Zhao,
Caicun Zhou,
Jianying Zhou,
Xiang-dong Zhou,
V. Kolek,
L. Koubková,
J. Roubec,
J. Skřičková,
M. Zemanova,
C. Chouaid,
W. Hilgers,
H. Léna,
D. Moro-Sibilot,
G. Robinet,
P. Souquet,
J. Alt,
H. Bischoff,
C. Grohé,
E. Laack,
S. Lang,
J. Panse,
C. Schulz,
K. Bogos,
E. Csánky,
Anea Fülöp,
Z. Horváth,
Judit Kósa,
I. Laczó,
G. Pajkos,
Z. Pápai,
Zsolt Pápai Székely,
V. Sárosi,
A. Somfay,
É. Ezer,
Anás Telekes,
J. Bar,
M. Gottfried,
N. Heching,
Alona Zer Kuch,
R. Bartolucci,
A. Bettini,
A. Delmonte,
M. Garassino,
M. Minelli,
F. Roila,
S. Atagi,
K. Azuma,
H. Goto,
K. Goto,
Yu Hara,
H. Hayashi,
T. Hida,
Kenya Kanazawa,
S. Kanda,
Y. H. Kim,
S. Kuyama,
T. Maeda,
M. Morise,
Y. Nakahara,
M. Nishio,
N. Nogami,
I. Okamoto,
H. Saito,
M. Shinoda,
S. Umemura,
T. Yoshida,
N. Claessens,
R. Cornelissen,
Lizza Heniks,
Jeroen Hiltermann,
E. Smit,
A. J. S. D. Brekel,
D. Kowalski,
S. Mańdziuk,
Robert Mróz,
M. Wojtukiewicz,
T. Ciuleanu,
D. Ganea,
A. Ungureanu,
A. Luft,
V. Moiseenko,
D. Sakaeva,
A. Smolin,
Alexander Vasilyev,
L. Vladimirova,
Igor Anasina,
J. Chovanec,
P. Demo,
R. Godal,
P. Kasan,
M. Stresko,
M. Urda,
E. Cho,
Joo‐Hang Kim,
Sang-We Kim,
Gyeong-Won Lee,
Jong-Seok Lee,
K. Lee,
K. Lee,
Yun-Gyoo Lee,
M. Molla,
M. D. Gómez,
J. I. D. Mingorance,
D. Casado,
M. L. Brea,
M. M. Tarruella,
T. M. Bueno,
A. N. Mendivil,
Luis Paz-Ares Rodríguez,
S. P. Aix,
M. Campelo,
G. Chang,
Yen-Hsun Chen,
C. Chiu,
T. Hsia,
Kang-Yun Lee,
Chien-Te Li,
Chin-Chou Wang,
Yu-Feng Wei,
Shang‐Yin Wu,
A. Alacacıoğlu,
I. Çiçin,
A. Demirkazık,
M. Erman,
T. Göksel,
H. Adamchuk,
O. Kolesnik,
A. Kryzhanivska,
Y. Ostapenko,
S. Shevnia,
Y. Shparyk,
G. Ursol,
N. Voitko,
I. Vynnychenko,
S. Babu,
A. Chiang,
W. Chua,
S. Dakhil,
A. Dowlati,
Basir Haque,
Rodney Jamil,
J. Knoble,
Shailena Lakhanpal,
Kailhong Mi,
P. Nikolinakos,
S. Powell,
H. Ross,
E. Schaefer,
J. Schneider,
Joseph E. Spahr,
D. Spigel,
J. Stilwill,
C. Sumey,
Michael Williamson
|
10 |
2019 |
10
🐜
|
|
🐜
|
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
11 auth.
K. Haratani,
H. Hayashi,
Y. Chiba,
K. Kudo,
K. Yonesaka,
R. Kato,
...
H. Kaneda,
Y. Hasegawa,
Kaoru Tanaka,
M. Takeda,
K. Nakagawa
|
9 |
2017 |
9
🐜
|
|
🐜
|
Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
21 auth.
A. Drilon,
Jeffrey W. Clark,
J. Weiss,
S. Ou,
D. Camidge,
B. Solomon,
G. Otterson,
L. Villaruz,
Gregory Riely,
R. Heist,
...
M. Awad,
G. Shapiro,
M. Satouchi,
T. Hida,
H. Hayashi,
D. Murphy,
Sherry Wang,
Sherry Li,
T. Usari,
K. Wilner,
P. Paik
|
8 |
2019 |
8
🐜
|
|
🐜
|
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
22 auth.
K. Haratani,
H. Hayashi,
Tae Tanaka,
H. Kaneda,
Y. Togashi,
K. Sakai,
Kentaro Hayashi,
S. Tomida,
Y. Chiba,
K. Yonesaka,
...
Yoshikane Nonagase,
T. Takahama,
J. Tanizaki,
Kaoru Tanaka,
T. Yoshida,
K. Tanimura,
M. Takeda,
H. Yoshioka,
Tadashi Ishida,
T. Mitsudomi,
K. Nishio,
K. Nakagawa
|
8 |
2017 |
8
🐜
|
|
🐜
|
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
13 auth.
J. Tanizaki,
K. Haratani,
H. Hayashi,
Y. Chiba,
Yasushi Nakamura,
K. Yonesaka,
K. Kudo,
H. Kaneda,
Y. Hasegawa,
Kaoru Tanaka,
...
M. Takeda,
Akihiko Ito,
K. Nakagawa
|
7 |
2017 |
7
🐜
|
|
🐜
|
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
17 auth.
K. Isomoto,
K. Haratani,
H. Hayashi,
S. Shimizu,
S. Tomida,
T. Niwa,
T. Yokoyama,
Y. Fukuda,
Y. Chiba,
R. Kato,
...
J. Tanizaki,
Kaoru Tanaka,
M. Takeda,
T. Ogura,
T. Ishida,
Akihiko Ito,
K. Nakagawa
|
7 |
2020 |
7
🐜
|
|
🐜
|
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
13 auth.
J. Tanizaki,
I. Okamoto,
T. Okabe,
K. Sakai,
Kaoru Tanaka,
H. Hayashi,
H. Kaneda,
K. Takezawa,
K. Kuwata,
Haruka Yamaguchi,
...
E. Hatashita,
K. Nishio,
K. Nakagawa
|
7 |
2012 |
7
🐜
|
|
🐜
|
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
14 auth.
H. Kawakami,
J. Tanizaki,
Kaoru Tanaka,
K. Haratani,
H. Hayashi,
M. Takeda,
K. Kamata,
M. Takenaka,
M. Kimura,
T. Chikugo,
...
Takao Sato,
M. Kudo,
Akihiko Ito,
K. Nakagawa
|
7 |
2017 |
7
🐜
|
|
🐜
|
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
21 auth.
P. Janne,
C. Baik,
Wu-Chou Su,
M. Johnson,
H. Hayashi,
M. Nishio,
Dong-Wan Kim,
M. Koczywas,
K. Gold,
C. Steuer,
...
H. Murakami,
J. Yang,
Sang-We Kim,
M. Vigliotti,
R. Shi,
Zhenhao Qi,
Yang Qiu,
Lihui Zhao,
D. Sternberg,
Channing Yu,
H. Yu
|
6 |
2021 |
6
🐜
|
|
🦁
|
The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer
14 auth.
H. Hayashi,
T. Arao,
Y. Togashi,
Hiroaki Kato,
Y. Fujita,
M. Velasco,
Hideharu Kimura,
Kazuko Matsumoto,
Kaoru Tanaka,
I. Okamoto,
...
Akihiko Ito,
Y. Yamada,
Kazuhiko Nakagawa,
K. Nishio
|
6 |
2013 |
6
🦁
|
|
🐜
|
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
17 auth.
H. Akamatsu,
Y. Toi,
H. Hayashi,
D. Fujimoto,
M. Tachihara,
N. Furuya,
S. Otani,
J. Shimizu,
N. Katakami,
K. Azuma,
...
N. Miura,
K. Nishino,
S. Hara,
S. Teraoka,
S. Morita,
K. Nakagawa,
N. Yamamoto
|
6 |
2021 |
6
🐜
|
